Ligelizumab

Ligelizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetIGHE
Clinical data
Other namesQGE031
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6534H10000N1716O2038S44
Molar mass146612.49 g·mol−1

Ligelizumab (INN; development code QGE031) is a humanized IgG1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria.[1] It is an anti-IgE that binds to IGHE an acts as an immunomodulator.[2][3]

This drug was developed by Novartis Pharma AG. Research funded by Novartis Pharma[4] concluded that Ligelizumab was more effective in treating chronic spontaneous urticaria than omalizumab or placebo.[5]

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Ligelizumab, American Medical Association.
  2. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2). 2012.
  3. ↑ Kocatürk, Emek; Maurer, Marcus; Metz, Martin; Grattan, Clive (2017-01-10). "Looking forward to new targeted treatments for chronic spontaneous urticaria". Clinical and Translational Allergy. 7: 1. doi:10.1186/s13601-016-0139-2. ISSN 2045-7022. PMC 5223554. PMID 28078079.
  4. ↑ Novartis Pharmaceuticals (2018-10-02). "A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)". {{cite journal}}: Cite journal requires |journal= (help)
  5. ↑ Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, et al. (October 2019). "Ligelizumab for Chronic Spontaneous Urticaria". The New England Journal of Medicine. 381 (14): 1321–1332. doi:10.1056/NEJMoa1900408. PMID 31577874.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.